Investigational drug · Phase 2
CLN-049
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "CLN-049"
First trial start
2021
Nov 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CLN-049", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- TP53-mutated MDS and AML
Approved drugs for the same conditions: Acute myeloid leukemia · Myelodysplastic syndromes · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "CLN-049" as an intervention, largest first.
Cullinan Therapeutics Inc.Industry
NCT05143996 · 275 participants (planned) · Start Nov 18, 2021 · Primary completion Dec 30, 2029
Drug: CLN-049 · For: Relapsed/Refractory Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); TP53-mutated MDS and AML
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 17 sites in all
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML PatientsNot yet recruiting
Cullinan Therapeutics Inc.Industry
NCT07722767 · 90 participants (planned) · Start Oct 15, 2026 · Primary completion Sep 30, 2027
Drug: CLN-049; Azacitidine and 1 more · For: AML (Acute Myeloid Leukemia)
Sites: Duarte, California; Miami, Florida; Atlanta, Georgia · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Rational design of next-generation FLT3 inhibitors in acute myeloid leukemia: From laboratory to clinics.
Gao S, Wang X, Zhao X, et al. · Eur J Med Chem 2026
- A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.
Mehta NK, Pfluegler M, Meetze K, et al. · J Immunother Cancer 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.